RegulatoryMay 7, 2026, 04:23 PM
Quoin Pharma QRX003 Gets US FDA Fast Track, Japan ODD; Q1 Net Loss $5M
AI Summary
Quoin Pharmaceuticals announced significant regulatory progress for its lead product candidate, QRX003, including US FDA Fast Track Designation and MHLW confirmation for Orphan Drug Designation and Fast Track review in Japan. The company also filed for Breakthrough Medicine Designation with the Saudi FDA and received positive feedback from the US FDA regarding a single Phase 3 study for marketing approval. Additionally, Quoin reported a net loss of approximately $5 million for Q1 2026, an increase from $3.8 million in Q1 2025, and held approximately $14 million in cash, cash equivalents, and marketable securities.
Key Highlights
- US FDA granted Fast Track Designation to QRX003 lotion (4%) for Netherton Syndrome.
- FDA indicated a single Phase 3 study may be sufficient for QRX003 US marketing approval.
- Submitted application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003.
- Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003.
- On track to complete QRX003 Phase 3 patient recruitment by end of 2026, with potential NDA filing in 2027.
- Initiating clinical testing for QRX009 in Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex.
- Q1 2026 net loss was approximately $5 million, compared to $3.8 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled approximately $14 million as of March 31, 2026.
Price Impact
More from QNRX